Sale of medical devicesManufacture and sale of medical pharmaceuticalsManufacture and sale of regenerative medicine productsManufacture, procurement, and sale of pharmaceutical raw materials
Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
162 EVENTS
Establishment of Japan Chemical Research Co., Ltd.
Founded Nippon Chemical Research
Established Mikage Factory in Higashinada-ku, Kobe City, Hyogo Prefecture
Opened the Mikage Plant in Higashinada-ku, Kobe, Hyogo
Established a method for refining urokinase (thrombolytic agent) raw material
Established a purification method for urokinase drug substance, a thrombolytic agent
Set up a research institute within Mikage Factory
Opened a research laboratory at the Mikage Plant
Relocated the research institute to Chuo-ku, Kobe City, Hyogo Prefecture
Relocated the research laboratory to Chuo-ku, Kobe, Hyogo
Obtained manufacturing approval for urokinase preparations and raw solutions
Received manufacturing approval for urokinase drug product and bulk solution
Obtained import approval for human growth hormone preparation "Growlum"
Received import approval for Growlum, a human growth hormone product
Opened Tokyo Office in Shibuya-ku, Tokyo
Opened the Tokyo Office in Shibuya-ku, Tokyo
Established Nishishin Factory in Nishishin Industrial Park, Nishi-ku, Kobe City, Hyogo Prefecture
Opened the Seishin Plant in Nishi-ku, Kobe, Hyogo (Seishin Industrial Park)
Relocated the research institute adjacent to Nishishin Factory
Relocated the research laboratory to a site adjacent to the Seishin Plant
Registered as a over-the-counter listed stock with the Japan Securities Dealers Association
Registered as an over-the-counter stock with the Japan Securities Dealers Association
Obtained manufacturing approval for genetically engineered human growth hormone preparation "Growject® 4IU"
Received manufacturing approval for GROWJECT™ Injection 4IU, a recombinant human growth hormone product
Relocated headquarters to current location at Kasugacho, Ashiya City, Hyogo Prefecture
Relocated headquarters to Kasuga-cho, Ashiya, Hyogo (current location)
Launched "TwinJector® EZ" pressure injector without needle for "Growject®"
Launched TWINJECTOR® EZ, a needle-free pressure injector for GROWJECT™
Constructed and relocated research institute to Kobe High-Tech Park in Nishi-ku, Kobe City, Hyogo Prefecture
Relocated the research laboratory to Nishi-ku, Kobe, Hyogo (Kobe High-Tech Park)
Obtained manufacturing approval for urinastatin raw solution "JCR"
Received manufacturing approval for Ulinastatin Bulk Solution “JCR,” a protease inhibitor drug substance
Approval for manufacturing of Urinastatin raw material "JCR" (protein-degrading enzyme inhibitor raw material)
Established the Nish-Shin-Minami Factory in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo Prefecture
Opened the Seishin South Plant in Kobe High-Tech Park
Listed on the Osaka Securities Exchange Second Section
Listed on the Second Section of the Osaka Securities Exchange
Established 'JCR Biopharmaceuticals, Inc.' in the United States
Established JCR Biopharmaceuticals, Inc. in the United States
Established a joint venture 'Jiexi Pharmaceutical Co., Ltd.' with Beijing Shanhai Pharmaceutical and Health Development Co., Ltd. in China
Established Jiexi Pharmaceutical Co., Ltd. in China through a joint venture with Beijing Shanhe Medical & Health Development Co., Ltd., wholly owned by Beijing Hospital
Established a joint venture "Jiexi Pharmaceutical Co., Ltd." with Beijing Shanhai Medical and Health Development Co., Ltd. (100% owned by Beijing Hospital, China)
Started import and sales of injection accessories 'Conijector® Pen' for 'Glowject®'
Began importing and marketing the KONYJECTOR® Pen, an injection aid for GROWJECT™
Established a medical device sales company 'Family Health Rental Co., Ltd.' in Chuo-ku, Kobe City, Hyogo Prefecture
Established Family Health Rental Co., Ltd., a medical device sales company, in Chuo-ku, Kobe, Hyogo
Initiated sales partnership with Sumitomo Pharmaceutical Co., Ltd. for recombinant human growth hormone formulation 'Glowject® Injections 4IU'
Entered into a marketing alliance with Sumitomo Pharmaceuticals Co., Ltd. (now Sumitomo Pharma Co., Ltd.) for GROWJECT™ Injection 4IU
Started sales partnership with Sumitomo Pharmaceutical Co., Ltd. (now Sumitomo Pharma Co., Ltd.) for recombinant human growth hormone preparation "Growject® 4IU"
Succeeded to the manufacturing approval of leukopenia treatment 'Leukoprorol®' from Morinaga Milk Industry Co., Ltd.
Assumed manufacturing approval for Leukoprol®, a treatment for leukopenia, from Morinaga Milk Industry Co., Ltd.
Obtained manufacturing approval for 'Glowject® Injections 24IU' and 'Glowject® BC24'
Received manufacturing approval for GROWJECT™ Injection 24IU and GROWJECT™ BC24
Obtained additional indication approval for 'Glowject® Injections 4IU' for 'short stature due to Turner syndrome without epiphyseal closure'
Received approval for an additional indication for GROWJECT™ Injection 4IU for short stature in Turner syndrome without closed epiphyses
Established Kobe Factory in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo Prefecture
Opened the Kobe Plant in Kobe High-Tech Park
Launched recombinant human growth hormone formulations 'Glowject® Injections 1.33mg', 'Glowject® Injections 8mg', 'Glowject® BC8mg' and pen-type injector 'Glowject® Pen'
Launched GROWJECT™ Injection 1.33mg, GROWJECT™ Injection 8mg, GROWJECT™ BC8mg, and the GROWJECT™ Pen injector
Established 'Chromatec Co., Ltd.' in Nishinomiya City, Hyogo Prefecture for research and medical device sales
Established Chromatec Co., Ltd., a distributor of research and medical equipment, in Nishinomiya, Hyogo
Launched 'Glowject® Pen 0.1mg', a pen-type injector with mg increments to accommodate formulation unit changes
Launched GROWJECT™ Pen 0.1mg, a pen injector with 0.1 mg increments reflecting revised product specifications
Launched 'TwinJector® EZ II', a needleless pressure injector for 'Glowject®'
Launched TWINJECTOR® EZ II, a needle-free pressure injector for GROWJECT™
Established a clinical trial drug manufacturing center (currently Moritani Factory) in Nishi-ku, Kobe City, Hyogo Prefecture
Opened the Clinical Trial Product Manufacturing Center (now Murotani Plant) in Kobe High-Tech Park
Launched an improved version of 'Glowject® Pen', a dedicated injector for 'Glowject®', called 'BD PenJector™ 2'
Launched the BD PenJector™ 2, an improved injector for GROWJECT™
Started sales of imported raw materials of anticancer agent 'Paclitaxel' to Nippon Kayaku Co., Ltd.
Began marketing imported paclitaxel drug substance, an anticancer agent, to Nippon Kayaku Co., Ltd.
Launched 'Glowject®', an electric injection device dedicated to 'Glowject®'
Launched the GROWJECTER®, an electric injector for GROWJECT™
Established Moritani Factory in Nishi-ku, Kobe City, Hyogo Prefecture (reorganized from clinical trial drug manufacturing center)
Opened the Murotani Plant in Kobe High-Tech Park, reorganized from the Clinical Trial Product Manufacturing Center
Approval for additional efficacy of genetically modified human growth hormone preparation "Growject®" for "Adult Growth Hormone Deficiency"
Established Kobe West Factory as a manufacturing plant for human mesenchymal stem cells in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo Prefecture
Received approval for an additional indication for GROWJECT™ for adult growth hormone deficiency
Opened the Kobe Nishi Plant in Kobe High-Tech Park as a manufacturing facility for human mesenchymal stem cells
Launched "BD Penjector™3", the successor to the dedicated injector for "Growject®" "BD Penjector™2"
Launched the BD PenJector™ 3, the successor to the BD PenJector™ 2 injector for GROWJECT™
Launched the renal anemia treatment drug "Epoetin Alpha BS Injection "JCR""
Launched Epoetin Alfa BS Injection “JCR,” Japan’s first biosimilar for the treatment of renal anemia
Launched the first domestically produced biopharmaceutical for renal anemia, "Epoetin Alpha BS" (JCR)
Listed on the Second Section of the Tokyo Stock Exchange
Listed on the Second Section of the Tokyo Stock Exchange
Established "JCR Engineering Inc." in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo Prefecture, to manage pharmaceutical manufacturing equipment, facilities, and machinery
Established JCR Engineering Co., Ltd. in Kobe High-Tech Park to manage pharmaceutical manufacturing facilities, equipment, and instruments
Launched "Glowject®" dedicated electric injector "Glowject®"
Launched GROWJECTER® 2, the successor to the GROWJECTER® electric injector for GROWJECT™
Approval for additional efficacy of genetically modified human growth hormone preparation "Growject®" for "SGA short stature without epiphyseal closure"
JCR receives an Approval for Expanded Indication of Growject™ in Short Stature due to Small-for-Gestational Age (SGA)
JCR receives an approval for expanded indication of Growject™ in short stature due to Small-for-Gestational Age (SGA)
Established Kobe Active Pharmaceutical Ingredient Plant in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo Prefecture
Opened the Kobe API Plant in Nishi-ku, Kobe, Hyogo Prefecture (Kobe High-Tech Park)
Listed on the First Section of the Tokyo Stock Exchange
Listed on the First Section of the Tokyo Stock Exchange
Changed company name to JCR Pharma Co., Ltd.
Renamed to JCR Pharmaceuticals Co., Ltd.
Established Kobe Logistics Center in Kobe Tech Park, Nishi-ku, Kobe City, Hyogo Prefecture
Opened the Kobe Logistics Center in Nishi-ku, Kobe, Hyogo Prefecture (Kobe High-Tech Park)
Established market research company "JCR INTERNATIONAL SA" in Switzerland
Established JCR INTERNATIONAL SA, a market research company, in Switzerland
Launched Japan's first allogeneic regenerative medicine product "Temcell®HS Injection"
Launched TEMCELL™ HS Inj., Japan’s first allogeneic regenerative medicine product.
Established clinical trial drug manufacturing center and cell processing center within the research institute site
Opened a Clinical Trial Drug Manufacturing Center and a Cell Processing Center within the research institute premises
Obtained manufacturing and marketing approval for the liquid formulation of the recombinant human growth hormone product “Growject™
Obtained manufacturing and marketing approval for the liquid formulation of the recombinant human growth hormone product "Growject™"
Obtained approval for manufacturing and sales of liquid formulation of "Growject®"
Launched "Glowject®" liquid formulation dedicated electric injector "Glowject®L"
Launched “Growjecter® L,” an electric injection device dedicated to the liquid formulation of “Growject™
Launched "Growjecter® L," an electric injection device dedicated to the liquid formulation of "Growject™"
Established JCR USA, Inc., a global management company for clinical development in the United States
Established JCR USA, Inc. in the United States to oversee clinical development
Launched "Argalactosidase Beta BS Intravenous Infusion "JCR"", the company's first lysosomal storage disease enzyme preparation
Launched Agalsidase Beta BS Intravenous Infusion “JCR,” the Company’s first enzyme replacement therapy for lysosomal storage disorders
Launched the long-acting erythropoiesis-stimulating agent “Darbepoetin Alfa BS Injection ‘JCR’
Launched the long-acting erythropoiesis-stimulating agent "Darbepoetin Alpha BS" (JCR)
Launched the long-acting erythropoiesis-stimulating agent "Darbepoetin Alfa BS Injection ‘JCR"
Acquired all shares of US pharmaceutical research and development company "ArmaGen, Inc."
Merged with Family Health Rental Corporation
Acquired all shares of ArmaGen, Inc., a U.S. biopharmaceutical R&D company
Absorbed and merged Family Health Rental Co., Ltd.
The company "JCR DO BRASIL FARMACÊUTICOS IMPORTAÇÃO E EXPORTAÇÃO LTDA." which conducts clinical operations, pharmaceutical affairs, and development activities within the Federative Republic of Brazil has commenced business activities
JCR DO BRASIL PHARMACEUTICALS IMPORTATION AND EXPORTATION LTD. started operations
Co-developed a smartphone application software "Melon Diary®" for the dedicated injector "Growject®L" of "Growject®" in collaboration with PHC Corporation
Co-developed Meron Diary®, a smartphone app for the GROWJECTER® L injector for GROWJECT™, with PHC Corporation
Signed a contract with AstraZeneca K.K. for manufacturing the domestic raw liquid of the new coronavirus vaccine "AZD1222"
Entered into a manufacturing services agreement with AstraZeneca K.K. for domestic drug substance production of the COVID-19 vaccine AZD1222
Established a bio-research center in Nishi-ku, Kobe City, Hyogo Prefecture (Kobe High-Tech Park)
Opened the Bioresearch Center in Kobe High-Tech Park
Launched the genetically engineered Mucopolysaccharidosis Type II treatment drug "Izargo®: Intravenous infusion 10mg" in Japan
Launched IZCARGO™ for I.V. Infusion 10mg in Japan
At "WORLDSymposium™ 2022," the genetically engineered Mucopolysaccharidosis Type II treatment drug "Izargo®: Intravenous infusion" received the New Treatment Award
IZCARGO™ for Intravenous Infusion received the New Treatment Award at WORLDSymposium™ 2022
IZCARGO™ for Intravenous Infusion received the New Treatment Award at WORLD : Symposium : ™ 2022
Reclassified from the First Section of the Tokyo Stock Exchange to the Prime Market due to a review of market segments
Transferred the sales of "Agalsidase Beta BS Intravenous Infusion 'JCR'" to Sumitomo Pharma Co., Ltd.
Moved from the First Section to the Prime Market of the Tokyo Stock Exchange following the market restructuring
Transferred marketing of Agalsidase Beta BS Intravenous Infusion “JCR” to Sumitomo Pharma Co., Ltd.
Established "JCR Luxembourg S.A." in the Grand Duchy of Luxembourg
Established JCR Luxembourg S.A. as a European base for global distribution management
Established "JCR Luxembourg S.A." as the European base for global distribution management of Luxembourg Grand Duchy
Established "JCR Europe B.V." in the Kingdom of the Netherlands, a company overseeing clinical development
Established JCR Europe B.V. in the Netherlands to oversee clinical development
Selected for the Ministry of Economy, Trade and Industry’s program to strengthen biopharmaceutical manufacturing infrastructure for vaccine production
Established "AlliedCel Inc." in Chuo-ku, Kobe City, Hyogo Prefecture, jointly with Sysmex Corporation, to conduct research and development of regenerative medicine products
Acquired shares of the Taiwanese biopharmaceutical manufacturing and development contract company "Mycenax Biotech Inc."
Established AlliedCel Corporation with Sysmex Corporation to conduct R&D on regenerative medicine products
Acquired shares of Mycenax Biotech Inc., a Taiwanese biopharmaceutical CDMO
Established Kobe Science Park Center in Nishi-ku, Kobe City, Hyogo Prefecture
Opened the Kobe Science Park Center in Kobe Science Park
Obtained approval for the additional efficacy of the genetically engineered human growth hormone "Growject®" for "short stature with SHOX deficiency without epiphyseal closure"
Received approval for an additional indication for GROWJECT™ for short stature associated with SHOX deficiency without closed epiphyses
Launched a new electric injector "Growject® Duo" jointly developed with PHC Corporation for "Growject®"
Launched GROWJECTER® Duo, a new electric injector for GROWJECT™, co-developed with PHC Corporation
Revised corporate philosophy and core values
Revised the corporate philosophy and core values
Revised the corporate philosophy and core values : 9 : Adopted the corporate slogan “Life is Rare”
Established the corporate slogan "Life is Rare"
Adopted the corporate slogan “Life is Rare”
§07
News
6 ARTICLES
PHP Vulnerability Response Notice
JCR Pharmaceuticals has temporarily suspended certain services on its websites in response to a PHP vulnerability. No incidents, including data leaks, have been identified. Services will resume once necessary security measures are implemented and safety is confirmed.
Response to PHP Vulnerabilities
As a preventive measure against PHP vulnerabilities, the login functions of "Growth Hormone Pro" and "Mucopolysaccharidosis Pro" have been suspended since October 22, 2026. At present, no information leakage or other incidents have been confirmed, and the services are scheduled to resume after safety verification is completed. The corporate website and the same site (GLOBAL) have already been addressed.
Publication of a Shared Research Report
A research report on JCR Pharmaceuticals has been published by Shared Research Inc. The report can be viewed via the provided link.
JCR Pharma releases IR seminar video
We released a recording of the investor IR seminar "Bridge Salon" held on September 12, 2026. The video explains the company's business and growth strategy and answers questions from investors. The distribution period is until March 29, 2027.
JCR Pharmaceuticals to Speak at Bridge Salon Investor Seminar
JCR Pharmaceuticals Co., Ltd. will speak at Bridge Salon, an investor relations seminar for individual investors, on September 12, 2026. The company will explain its business and growth strategy. The event will be held in a hybrid format, with in-person and online participation. Advance registration is required, and the livestream will be free to watch.
JCR Pharma, Partial Correction of Shareholders' Meeting Notice
JCR Pharma announced that it had corrected errors in the notice of the 51st regular shareholders' meeting.
§08
Public records
GOV
National Tax Agency basic information6140001000905
Source: National Tax Agency Corporate Number Publication Site, basic three items